Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

625 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CpG island methylator phenotype classification improves risk assessment in pediatric T-cell Acute Lymphoblastic Leukemia.
Schäfer Hackenhaar F, Refhagen N, Hagleitner MM, van Leeuwen FN, Marquart HV, Madsen HO, Landfors M, Osterman P, Schmiegelow K, Flaegstad T, Jonsson OG, Kanerva J, Abrahamsson J, Heyman M, Noren-Nystrom U, Hultdin M, Degerman S. Schäfer Hackenhaar F, et al. Among authors: heyman m. Blood. 2025 Jan 22:blood.2024026027. doi: 10.1182/blood.2024026027. Online ahead of print. Blood. 2025. PMID: 39841000
DNA Methylation Adds Prognostic Value to Minimal Residual Disease Status in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Borssén M, Haider Z, Landfors M, Norén-Nyström U, Schmiegelow K, Åsberg AE, Kanerva J, Madsen HO, Marquart H, Heyman M, Hultdin M, Roos G, Forestier E, Degerman S. Borssén M, et al. Among authors: heyman m. Pediatr Blood Cancer. 2016 Jul;63(7):1185-92. doi: 10.1002/pbc.25958. Epub 2016 Feb 29. Pediatr Blood Cancer. 2016. PMID: 26928953 Clinical Trial.
A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
Enshaei A, O'Connor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, den Boer ML, Boer JM, de Groot-Kruseman HA, Marquart HV, Noren-Nystrom U, Schmiegelow K, Schwab C, Horstmann MA, Escherich G, Heyman M, Pieters R, Vora A, Moppett J, Moorman AV. Enshaei A, et al. Among authors: heyman m. Blood. 2020 Apr 23;135(17):1438-1446. doi: 10.1182/blood.2019003191. Blood. 2020. PMID: 32315382 Free article.
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Gottschalk Højfeldt S, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jónsson ÓG, Frandsen TL, Wolthers BO, Marquart HV, Vaitkeviciene G, Lepik K, Heyman M, Schmiegelow K, Albertsen BK. Gottschalk Højfeldt S, et al. Among authors: heyman m. Blood. 2021 Apr 29;137(17):2373-2382. doi: 10.1182/blood.2020006583. Blood. 2021. PMID: 33150360 Free article. Clinical Trial.
DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia.
Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, Heyman M, Jonmundsson G, Kanerva J, Schmiegelow K, Söderhäll S, Gustafsson MG, Lönnerholm G, Syvänen AC. Milani L, et al. Among authors: heyman m. Blood. 2010 Feb 11;115(6):1214-25. doi: 10.1182/blood-2009-04-214668. Epub 2009 Nov 25. Blood. 2010. PMID: 19965625 Free article.
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Toft N, Birgens H, Abrahamsson J, Bernell P, Griškevičius L, Hallböök H, Heyman M, Holm MS, Hulegårdh E, Klausen TW, Marquart HV, Jónsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Åsberg A, Schmiegelow K. Toft N, et al. Among authors: heyman m. Eur J Haematol. 2013 May;90(5):404-12. doi: 10.1111/ejh.12097. Epub 2013 Apr 2. Eur J Haematol. 2013. PMID: 23461707
The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK, Christensen RH, Shabaneh DN, Harila-Saari A, Heyman M, Jonsson OG, Wesenberg F, Rosthøj S, Schmiegelow K; Nordic Society of Pediatric Hematology, Oncology (NOPHO). Clemmensen KK, et al. Among authors: heyman m. Pediatr Blood Cancer. 2014 Apr;61(4):653-8. doi: 10.1002/pbc.24867. Epub 2013 Nov 22. Pediatr Blood Cancer. 2014. PMID: 24265159 Clinical Trial.
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi M, Söderhäll S, Schmiegelow K; Nordic Society of Paediatric Haematology, Oncology. Levinsen M, et al. Among authors: heyman m. Pediatr Blood Cancer. 2014 May;61(5):797-802. doi: 10.1002/pbc.24921. Epub 2014 Jan 3. Pediatr Blood Cancer. 2014. PMID: 24395436
Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-ALL treated according to the NOPHO ALL-1992 and ALL-2000 protocols.
Fogelstrand L, Staffas A, Wasslavik C, Sjögren H, Söderhäll S, Frost BM, Forestier E, Degerman S, Behrendtz M, Heldrup J, Karrman K, Johansson B, Heyman M, Abrahamsson J, Palmqvist L. Fogelstrand L, et al. Among authors: heyman m. Pediatr Blood Cancer. 2014 Mar;61(3):424-30. doi: 10.1002/pbc.24803. Epub 2013 Oct 8. Pediatr Blood Cancer. 2014. PMID: 24424791
Clinical features and early treatment response of central nervous system involvement in childhood acute lymphoblastic leukemia.
Levinsen M, Taskinen M, Abrahamsson J, Forestier E, Frandsen TL, Harila-Saari A, Heyman M, Jonsson OG, Lähteenmäki PM, Lausen B, Vaitkevičienė G, Asberg A, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Levinsen M, et al. Among authors: heyman m. Pediatr Blood Cancer. 2014 Aug;61(8):1416-21. doi: 10.1002/pbc.24981. Epub 2014 Feb 12. Pediatr Blood Cancer. 2014. PMID: 24623619 Clinical Trial.
625 results